ライフサイエンスコーパス: hepatocyte growth factor

1 tion of MET or its stimulation by the ligand hepatocyte growth factor.

2 uction of renal epithelial motility with the hepatocyte growth factor.

3 ctors, namely fibroblast growth factor 2 and hepatocyte growth factor.

4 d to 14 d by application of soluble VEGF and hepatocyte growth factor.

5 tic liver injury by regulating activation of hepatocyte growth factor.

6 ed by injection of an adenovector expressing hepatocyte growth factor.

7 hanisms, including proteolytic activation of hepatocyte growth factor.

8 everal RTKs, including Met, the receptor for hepatocyte growth factor.

9 t it suppressed tubulogenesis in response to hepatocyte growth factor.

10 hepatocyte growth factor, a mediator of CSC migration, w

11 r Kunitz type 2), a proteolytic inhibitor of hepatocyte growth factor activator (HGFA), which has a s

12 bitor of several serine proteases, including hepatocyte growth factor activator and matriptase.

13 In this study we investigated the roles of hepatocyte growth factor activator inhibitor (HAI)-1 and

14 nate Kunitz-type serine protease inhibitors, hepatocyte growth factor activator inhibitor (HAI)-1 or

15 olled by the Kunitz-type protease inhibitor, hepatocyte growth factor activator inhibitor (HAI-1).

16 mmation mutant caused by an insertion in the hepatocyte growth factor activator inhibitor gene 1 (hai

17 d precursor-like protein 2 (APLP2), bikunin, hepatocyte growth factor activator inhibitor type 2 (HAI

18 mma-catenin were driven by the expression of hepatocyte growth factor activator inhibitor Type I (HAI

19 Hepatocyte growth factor activator inhibitor-1 (HAI-1) i

20 tivity is tightly regulated by its inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1) s

21 MT-SP1 with regard to its cognate inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1),

22 iptase is regulated by its cognate inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1).

23 In this study, we delineated the role of hepatocyte growth factor activator inhibitor-2 (HAI-2) i

24 In addition, we showed that the hepatocyte growth factor activator, mitogen-activated pr

25 racrine growth factors such as endothelin 1, hepatocyte growth factor, alpha-melanocyte stimulating h

26 Hepatocyte growth factor and epidermal growth factors ca

27 tion, a baseline CAF signature consisting of hepatocyte growth factor and IL-12 was associated with t

28 Along with hepatocyte growth factor and its receptor MET (HGF-MET),

29 as well as differences in the expression of hepatocyte growth factor and PPAR-gamma, have been demon

30 d other growth-related pathways that involve hepatocyte growth factor and VEGF as well as the down-re

31 (12 CRVO, 6 BRVO) showed baseline levels of hepatocyte growth factor and VEGF of 168.2 +/- 20.1 pg/m

32 hat deserve further study include persephin, hepatocyte growth factor, and endocrine gland VEGF.

33 ascular endothelial growth factor, TGF-beta, hepatocyte growth factor, and galectin-1 gene expression

34 ssion of vascular endothelial growth factor, hepatocyte growth factor, and hyaluronic acid.

35 factors vascular endothelial growth factor, hepatocyte growth factor, and insulin-like growth factor

36 secreted vascular endothelial growth factor, hepatocyte growth factor, and insulin-like growth factor

37 ls such as epidermal growth factor (EGF) and hepatocyte growth factor, and is generally underexpresse

38 -chemokines, fibroblast growth factor-basic, hepatocyte growth factor, and migration inhibition facto

39 s of cultured fibroblasts identified VEGF-A, hepatocyte growth factor, and PDGF-C as candidate secret

40 ospondin 1, connective tissue growth factor, hepatocyte growth factor, and procollagen type I.

41 nteric neurons produce MET, the receptor for hepatocyte growth factor, and that loss of MET activity

42 tors, vascular endothelial growth factor and hepatocyte growth factor, and three markers of osteoblas

43 interleukin-6, tumor necrosis factor-alpha, hepatocyte growth factor, and transforming growth factor

44 lood levels of insulin-like growth factor-1, hepatocyte growth factor, and vascular endothelial growt

45 explains a modest proportion of circulating hepatocyte growth factor, Ang-2, and Tie-2.

46 R) and MET (the receptor tyrosine kinase for hepatocyte growth factors) are cell-surface tyrosine kin

47 graft (total i scores), with upregulation of hepatocyte growth factor at 24 months, indicating a time

48 Blockage of the c-met/hepatocyte growth factor axis attenuates HCC recurrence,

49 ion induced by RF ablation facilitates c-met/hepatocyte growth factor axis-dependent HCC tumor format

50 ion induced by RF ablation facilitates c-met/hepatocyte growth factor axis-dependent HCC tumor format

51 tor tyrosine kinase Sema-PSI in complex with hepatocyte growth factor beta-chain reveals the receptor

52 how VEGF-A stimulates paracrine secretion of hepatocyte growth factor by stromal cells, which induces

53 le RTKs, including VEGFR and the receptor of hepatocyte growth factor c-Met, which can drive tumor in

54 d cellular invasion through stimulation of a hepatocyte growth factor-c-Met signaling circuit, whereb

55 The hepatocyte growth factor/c-MET axis is implicated in tum

56 e signaling and mesenchymal feedback through hepatocyte growth factor/c-Met in SSc epidermis.

57 pathway, insulin-like growth factor pathway, hepatocyte growth factor/c-MET pathway and growth factor

58 s potentially regulated by the key oncogenic hepatocyte growth factor/c-MET pathway in PEL.

59 Moreover, we discovered that hepatocyte growth factor/c-Met signaling is required for

60 line-derived neurotrophic factor/c-Ret, and hepatocyte growth factor/c-Met signaling.

61 In cell culture, MK-2461 inhibited hepatocyte growth factor/c-Met-dependent mitogenesis, mi

62 ansgenic mice through dual activation of pro-hepatocyte growth factor-cMet-Akt-mTor proliferation/sur

63 In multivariable-adjusted models, sTie-2 and hepatocyte growth factor concentrations were associated

64 by ETS1 via this second site is enhanced by hepatocyte growth factor-dependent ETS1 activation, ther

65 transformed human epithelial lung cells in a hepatocyte growth factor-dependent manner.

66 rferon gamma-induced protein 10 (IP-10), and hepatocyte growth factor differentiated between patients

67 but >/=50% of patients showed reductions in hepatocyte growth factor, endocrine gland VEGF, insulin-

68 th factor, insulin-like growth factor-1, and hepatocyte growth factor equally with syngeneic CDCs.

69 in serglycin exhibited diminished levels of hepatocyte growth factor expression and impaired develop

70 r epithelium, which coincided with increased hepatocyte growth factor expression.

71 Furthermore, ICOS-Fc downmodulated hepatocyte growth factor facilitated the epithelial-to-m

72 interleukin-1 receptor antagonist [IL-1ra], hepatocyte growth factor, fatty acid-binding protein 4,

73 genetic proteins, endothelins, steel factor, hepatocyte growth factor, fibroblast growth factors, and

74 Last, we identify hepatocyte growth factor ( HGF) as a novel transcription

75 ine interleukin (IL)-7 and the beta-chain of hepatocyte growth factor (HGF) aggregate to form a natur

76 ted GI and liver GVHD diagnostic biomarkers, hepatocyte growth factor (HGF) and cytokeratin fragment

77 Hepatocyte growth factor (HGF) and epidermal growth fact

78 Their expression is up-regulated by hepatocyte growth factor (HGF) and epidermal growth fact

79 mechanisms of barrier enhancement induced by hepatocyte growth factor (HGF) and evaluated the role of

80 epato-inductive growth factors (GFs) such as hepatocyte growth factor (HGF) and hepato-disruptive GFs

81 ne tyrosine kinase cell surface receptor for hepatocyte growth factor (HGF) and is structurally relat

82 Functional assays identified hepatocyte growth factor (HGF) and its primary receptor

83 Hepatocyte growth factor (HGF) and its receptor (c-Met)

84 Signaling of hepatocyte growth factor (HGF) and its receptor c-Met ca

85 Hepatocyte growth factor (HGF) and its receptor cMET aug

86 Hepatocyte growth factor (HGF) and its receptor MET repr

87 The hepatocyte growth factor (HGF) and its receptor, c-Met,

88 The hepatocyte growth factor (HGF) and its receptor, the tra

89 ained significantly higher concentrations of hepatocyte growth factor (HGF) and pigment epithelium-de

90 The hepatocyte growth factor (HGF) and the HGF receptor Met

91 We tested the hypothesis that hepatocyte growth factor (HGF) and the HGF receptor MET

92 s fate selection to skewing in production of hepatocyte growth factor (HGF) and transforming growth f

93 Hepatocyte growth factor (HGF) and vascular endothelial

94 Hepatocyte growth factor (HGF) and vascular endothelial

95 f LSEC-derived angiocrine factors, including hepatocyte growth factor (HGF) and Wnt2.

96 erythropoietin, stem cell factor (SCF), and hepatocyte growth factor (HGF) are also present at highe

97 en, we identified the aberrant expression of hepatocyte growth factor (HGF) as a crucial element in A

98 e levels of interleukin 6 (IL-6) at 6 hours, hepatocyte growth factor (HGF) at 72 hours, and vascular

99 in vivo glioblastoma models characterized by hepatocyte growth factor (HGF) autocrine or paracrine ac

100 The hepatocyte growth factor (HGF) binding antibody rilotumu

101 Hepatocyte growth factor (HGF) binds to its target recep

102 The ligand hepatocyte growth factor (HGF) can also be overexpressed

103 ated signaling through binding to its ligand hepatocyte growth factor (HGF) can modulate the apoptosi

104 inical implications was the observation that hepatocyte growth factor (HGF) confers resistance to the

105 We find that fibroblast secretion of hepatocyte growth factor (HGF) fosters the ability of tr

106 Hepatocyte growth factor (Hgf) gene expression was suppr

107 cancer (CRC) cells produces mutations in the hepatocyte growth factor (HGF) gene.

108 Increases in hepatocyte growth factor (HGF) in liver sinusoidal endot

109 lysates indicated a greater concentration of hepatocyte growth factor (HGF) in resistant tumors than

110 atectomy demonstrated enhanced expression of hepatocyte growth factor (HGF) in the liver compared to

111 tokine containing IL-7 and the beta-chain of hepatocyte growth factor (HGF) in the supernatant of cul

112 Hepatocyte growth factor (HGF) induces cell migration an

113 Hepatocyte growth factor (HGF) is a heparin-binding cyto

114 Hepatocyte growth factor (HGF) is a mitogen and insulino

115 Hepatocyte growth factor (HGF) is a mitogen required for

116 Hepatocyte growth factor (HGF) is a multipotent endogeno

117 Hepatocyte growth factor (HGF) is an activating ligand o

118 eral auditory structures, we discovered that hepatocyte growth factor (Hgf) is expressed in the futur

119 Hepatocyte growth factor (HGF) mediated signaling promot

120 f c-Met by EGFR occurs without production of hepatocyte growth factor (HGF) or another secreted facto

121 sion and Akt phosphorylation downstream from hepatocyte growth factor (HGF) or epidermal growth facto

122 Met receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) play an important role in

123 Hepatocyte growth factor (HGF) plays central roles in tu

124 We show that neuregulin 1 (NRG1) and hepatocyte growth factor (HGF) provide resistance to MEK

125 We report that engagement of the hepatocyte growth factor (HGF) receptor c-Met by heart-p

126 with aberrant upregulation of the oncogenic hepatocyte growth factor (HGF) receptor c-MET in PNETs.

127 CD82 has been physically linked to cMet, the hepatocyte growth factor (HGF) receptor, in tumor cells,

128 ated that these endothelial cells supply the hepatocyte growth factor (HGF) required for the chemotac

129 alysis showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of

130 fibroblasts, at least in part, by mediating hepatocyte growth factor (HGF) secretion through its eff

131 ion of a TGFbeta gene signature and elevated hepatocyte growth factor (HGF) secretion.

132 We found the roles of hepatocyte growth factor (HGF) signaling in stria vascul

133 Furthermore, inhibition of paracrine factor hepatocyte growth factor (HGF) signaling in vivo suppres

134 Hepatocyte growth factor (HGF) signaling promotes tumor

135 Hepatocyte growth factor (HGF) signaling via c-Met is kn

136 at HACE1 and Rac1 interaction is enhanced by hepatocyte growth factor (HGF) signalling, a Rac activat

137 modeling strategy to systematically unravel hepatocyte growth factor (HGF) stimulated phosphoinositi

138 stain substantial cell-generated forces upon hepatocyte growth factor (HGF) stimulation, consistent w

139 of interleukin (IL)-7 and the beta-chain of hepatocyte growth factor (HGF) that had lymphopoietic st

140 bility of insulin-like growth factor (IGF)-1/hepatocyte growth factor (HGF) to activate resident endo

141 l (SC) niche in sarcoma development by using Hepatocyte Growth Factor (HGF) to perturb the niche micr

142 Binding of hepatocyte growth factor (HGF) to the receptor tyrosine

143 cular, we found that the MET receptor ligand hepatocyte growth factor (HGF) was especially active in

144 High levels of hepatocyte growth factor (HGF), a healing factor with re

145 Hepatocyte growth factor (HGF), an endogenous tissue rep

146 igration both in the absence and presence of hepatocyte growth factor (HGF), an established inducer o

147 Gene expression and gene dosage of MACC1, hepatocyte growth factor (HGF), and hepatocyte growth fa

148 basic fibroblast growth factor (FGF-basic), hepatocyte growth factor (HGF), and migration inhibition

149 tivation of c-Met in response to its ligand, hepatocyte growth factor (HGF), and partially blocked th

150 rdiac myocytes and fibroblasts was driven by hepatocyte growth factor (HGF), and platelet activation

151 o drive tumor progression (e.g. VEGF, MMP-9, hepatocyte growth factor (HGF), and RANKL).

152 Epidermal growth factor (EGF), hepatocyte growth factor (HGF), and vascular endothelial

153 Expression of the MET ligand, hepatocyte growth factor (HGF), by tissues innervated by

154 tent, strictly additive, survival effects of hepatocyte growth factor (HGF), ciliary neurotrophic fac

155 that c-Met, the tyrosine kinase receptor for hepatocyte growth factor (HGF), contributes to the pro-t

156 the role of Nogo-B in interleukin-6 (IL-6), hepatocyte growth factor (HGF), epidermal growth factor

157 signaling mediated by c-MET and its ligand, hepatocyte growth factor (HGF), has been implicated in m

158 rosine kinase MET, which is the receptor for hepatocyte growth factor (HGF), has been implicated in o

159 tory protein 1alpha (MIP-1alpha), MIP-1beta, hepatocyte growth factor (HGF), IFN-gamma-inducible prot

160 e transmembrane tyrosine kinase receptor for hepatocyte growth factor (HGF), is known to function as

161 m, glial-derived neurotrophic factor (GDNF), hepatocyte growth factor (HGF), or fibronectin.

162 c-Met, a high-affinity receptor for hepatocyte growth factor (HGF), plays a critical role in

163 MET, the receptor for hepatocyte growth factor (HGF), plays an important role

164 eta signaling induces fibroblasts to secrete hepatocyte growth factor (HGF), reciprocally driving col

165 levels of epidermal growth factor (EGF) and hepatocyte growth factor (HGF), reduced FGF, EGFR, and H

166 The overexpression of c-Met and/or hepatocyte growth factor (HGF), the amplification of the

167 tial screening-interleukin 6, interleukin 8, hepatocyte growth factor (HGF), tissue inhibitor of meta

168 be phosphorylated by stimulation of EGF and hepatocyte growth factor (HGF), two promoting factors fo

169 factors fibroblast growth factor-2 (FGF-2), hepatocyte growth factor (HGF), vascular endothelial gro

170 econd, hepatic RF ablation was performed for hepatocyte growth factor (HGF), vascular endothelial gro

171 gh levels of murine interleukin-6 (IL-6) and hepatocyte growth factor (HGF), whereas cancer cells pro

172 oculomotor neurons to respond to CXCL12 and hepatocyte growth factor (HGF), which are growth promoti

173 conducted in the absence of the MET ligand, hepatocyte growth factor (HGF), which is abundant in the

174 he process involves several factors, such as hepatocyte growth factor (HGF), which restrains hepatic

175 We show that hepatocyte growth factor (HGF), which synergizes with ac

176 P2 mesenchymal cells secreted high levels of hepatocyte growth factor (HGF), which we propose acts in

177 ative and angiogenic functions of hEPCs in a hepatocyte growth factor (HGF)-dependent manner.

178 ffector of Met signaling and is required for hepatocyte growth factor (HGF)-induced cell migration.

179 We previously reported that hepatocyte growth factor (HGF)-mediated increases in EC

180 Notably, C1GALT1 attenuation also suppressed hepatocyte growth factor (HGF)-mediated phosphorylation

181 The hepatocyte growth factor (HGF)-MET pathway supports seve

182 tically inactive forms of RPTP-beta, reduces hepatocyte growth factor (HGF)-stimulated Met tyrosine p

183 we examined the impact of EGFR signaling on hepatocyte growth factor (HGF)-stimulated migration and

184 osine kinases could be MET, the receptor for hepatocyte growth factor (HGF).

185 ar matrix, which form tubules in response to hepatocyte growth factor (HGF).

186 at model using a mesenchymal stem cell-based hepatocyte growth factor (HGF).

187 vely targets the ligand of the MET receptor, hepatocyte growth factor (HGF).

188 c-MET is the high-affinity receptor for the hepatocyte growth factor (HGF).

189 ial-to-mesenchymal transition in response to hepatocyte growth factor (HGF).

190 factor stimulation by its endogenous ligand, hepatocyte growth factor (HGF).

191 hemotaxis in response to the chemoattractant hepatocyte growth factor (HGF).

192 ascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF).

193 the oncogenic receptor, c-Met, by its ligand hepatocyte growth factor (HGF).

194 es with ultrasensitive response functions to Hepatocyte Growth Factor (HGF).

195 ansition into an active state in response to hepatocyte growth factor (HGF).

196 n and cytotoxicity in response to its ligand hepatocyte growth factor (HGF).

197 in the presence of EMT-inducing signals like Hepatocyte Growth Factor (HGF).

198 tein kinase pathway, causing them to secrete hepatocyte growth factor (HGF).

199 The hepatocyte growth factor (HGF)/c-Met signaling axis is d

200 CCN1/Cyr61 overlap with those induced by the hepatocyte growth factor (HGF)/c-Met signaling pathway.

201 Hepatocyte growth factor (HGF)/c-Met supports a pleiotro

202 The relative contribution of hepatocyte growth factor (HGF)/MET and epidermal growth

203 Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumo

204 The hepatocyte growth factor (HGF)/Met receptor signaling pa

205 Hepatocyte growth factor (HGF)/Met signaling has critica

206 rcuitry is necessary for spatially localized hepatocyte growth factor (HGF)/MET signaling that drives

207 1) is a recently discovered regulator of the hepatocyte growth factor (HGF)/Met/mitogen-activated pro

208 ivated in an autocrine fashion by its ligand hepatocyte growth factor (HGF)/scatter factor in some CC

209 ke peptide-1 (GLP-1) and the NK1 fragment of hepatocyte growth factor (HGF/NK1) in beta-cells, improv

210 n PPFs: angiopoietin-2 (r = 0.40, P = .001), hepatocyte growth factor (HGF; r = 0.31, P = .02), and e

211 In patients receiving chemotherapy, hepatocyte growth factor, IL-8, IL-1RA, and CXCL9 (P = .

212 tor-alpha; tumor necrosis factor receptor-1; hepatocyte growth factor; IL-8; elafin, a skin-specific

213 ion study for circulating Ang-2, sTie-2, and hepatocyte growth factor in 3571 Framingham Heart Study

214 ed by higher levels of syndecan-1, VEGF, and hepatocyte growth factor in exosomes secreted by heparan

215 ds to a significantly elevated production of hepatocyte growth factor in hepatic stellate cells posti

216 gration, and a diminished ability to undergo hepatocyte growth factor-induced epithelial-mesenchymal

217 paired apical polarization and inhibition of hepatocyte growth factor-induced tubulogenesis in Tuba k

218 associated with reduced cellular binding of hepatocyte growth factor, inhibition of pERK-1/2 signali

219 ression of the cognate matriptase inhibitor, hepatocyte growth factor inhibitor (HAI)-2.

220 Further, a significant delay in hepatocyte growth factor-initiated signaling, including

221 gen activator inhibitor-1 (PAI-1), resistin, hepatocyte growth factor, interleukin-6 (IL-6), and TNF-

222 ich encodes the receptor tyrosine kinase for hepatocyte growth factor, is a target of miR-449.

223 receptor tyrosine kinase and between MSP and hepatocyte growth factor, it is well established that th

224 ayed a 55-fold increase in the expression of hepatocyte growth factor, known to be involved in myogen

225 activation of Ron, through ligand binding by hepatocyte growth factor-like protein (HGFL), induces th

226 x, and that activation of Ron by its ligand, hepatocyte growth factor-like protein (HGFL), stimulates

227 After binding of its cognate ligand hepatocyte growth factor, Met signaling confers mitogeni

228 Aberrant HGF-MET (hepatocyte growth factor-met proto-oncogene) signaling a

229 and activation of, and dependence upon, the hepatocyte growth factor/met proto-oncogene pathway.

230 fficacy with expression levels of MET ligand hepatocyte growth factor, O(6)-methylguanine-DNA methylt

231 gested that patients with high expression of hepatocyte growth factor or unmethylated O(6)-methylguan

232 re inversely associated with baseline plasma hepatocyte growth factor (P = .019).

233 entin (P<0.0001, logistic regression model), hepatocyte growth factor (P<0.0001), alpha-smooth muscle

234 plasma angiogenesis factors (angiopoietin 2; hepatocyte growth factor; platelet-derived growth factor

235 2), its soluble receptor Tie-2 (sTie-2), and hepatocyte growth factor play important roles in angioge

236 After partial hepatectomy, BM SPCs provide hepatocyte growth factor, promote hepatocyte proliferati

237 Hepatocyte growth factor receptor (also known as Met), a

238 hancing RTKs, including EGF receptor, ErbB2, hepatocyte growth factor receptor (c-Met), EphA2, rearra

239 epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-MET).

240 like kinase beta, estrogen receptor, and the hepatocyte growth factor receptor (HGFR or MET).

241 the beta2-adrenoceptor with dopamine, or the hepatocyte growth factor receptor (HGFR/c-MET) with an a

242 increases in the EGF receptor (EGFR) and the hepatocyte growth factor receptor (Met) expression and a

243 The overexpression and overactivation of hepatocyte growth factor receptor (Met) in various cance

244 f MACC1, hepatocyte growth factor (HGF), and hepatocyte growth factor receptor (MET) were assessed us

245 ork and frequent overexpression of EGFR, the hepatocyte growth factor receptor (MET), pRPS6, and Ki67

246 ntinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endoth

247 ukemia viral oncogene homolog 2 (ERBB2), and hepatocyte growth factor receptor (MET).

248 ermal growth factor receptor 2 (HER2)], and [hepatocyte growth factor receptor (MET)] addicted cancer

249 wth arrest specific protein 6, oncostatin M, hepatocyte growth factor receptor etc.

250 e found to have amplification of EGFR or the hepatocyte growth factor receptor gene (MET) as well.

251 to an autoinhibitory segment observed in the hepatocyte growth factor receptor kinase but different f

252 epithelial cells express high levels of the hepatocyte growth factor receptor Met, and both the rece

253 lathrin exist in complex with either AP-3 or hepatocyte growth factor receptor substrate (Hrs).

254 cosylation of IPT/TIG domains of plexins and hepatocyte growth factor receptor was not affected in TM

255 ppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-depen

256 (syndecan-1-mediated signaling, signaling of hepatocyte growth factor receptor, and growth hormone si

257 epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor, to intracellular sign

258 orylation of the epidermal growth factor and hepatocyte growth factor receptors, thereby attenuating

259 celerates receptor turnover, whereas loss of hepatocyte growth factor-regulated substrate (Hrs) rescu

260 RT-0 is formed by two subunits known as Hrs (hepatocyte growth factor-regulated substrate) and STAM (

261 uired for transport (ESCRT)-0 component Hrs [hepatocyte growth factor-regulated tyrosine kinase subst

262 Furthermore, we identify hepatocyte growth factor-regulated tyrosine kinase subst

263 ited into an endosomal subdomain enriched in hepatocyte growth factor-regulated tyrosine kinase subst

264 Additionally, hepatocyte growth factor-regulated tyrosine kinase subst

265 n and the ubiquitin-binding ESCRT components hepatocyte growth factor-regulated tyrosine kinase subst

266 CLR*RAMP2 was sensitive to overexpression of hepatocyte growth factor-regulated tyrosine kinase subst

267 that the endosomal proteins Myopic (Mop) and Hepatocyte growth factor-regulated tyrosine kinase subst

268 ets ENaC to lysosomes, we tested the role of hepatocyte growth factor-regulated tyrosine kinase subst

269 examined the role of ESCRT-0 component Hrs (hepatocyte growth factor-regulated tyrosine kinase subst

270 n as the top positive correlated gene, while hepatocyte growth factor-regulated tyrosine kinase subst

271 fensin 1 and E-cadherin, and upregulation of hepatocyte growth factor-regulated tyrosine kinase subst

272 d medium derived from myofibroblasts or with hepatocyte growth factor restored clonogenic potential i

273 ybrid cytokine of IL-7 and the beta chain of hepatocyte growth factor (rIL-7/HGFbeta) that stimulates

274 The growth and motility factor Hepatocyte Growth Factor/Scatter Factor (HGF/SF) and its

275 r tyrosine kinase, c-Met, activating it in a hepatocyte growth factor/scatter factor (HGF/SF) indepen

276 Hepatocyte growth factor/scatter factor (HGF/SF) stimula

277 ceptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), modula

278 he MET-tyrosine kinase receptor activated by hepatocyte growth factor/scatter factor (HGF/SF).

279 l cells to the cognate ligand for c-Met, pro-hepatocyte growth factor/scatter factor (proHGF/SF), thr

280 Thirty years later, Met and its ligand hepatocyte growth factor/scatter factor are promising ta

281 ted these epidemiological findings using the hepatocyte growth factor/scatter factor transgenic mouse

282 a unique nonglycosylated active fragment of hepatocyte growth factor/scatter factor, 1K1, which acts

283 lls, and is amplified by Met activation with hepatocyte growth factor/scatter factor.

284 volved in beta-cell proliferation, including hepatocyte growth factor, serotonin synthesis, and integ

285 nist, interferon gamma-inducible protein 10, hepatocyte growth factor, soluble p75 tumor necrosis fac

286 on of c-Met protein and mRNA transcripts and hepatocyte growth factor-stimulated ERK and Akt phosphor

287 Activation of the Met receptor after hepatocyte growth factor stimulation in vitro promotes a

288 Our results now show that hepatocyte growth factor synthesized by myofibroblasts a

289 interleukin 18 and IP-10 but lower levels of hepatocyte growth factor than those without such abnorma

290 Despite the presence of hepatocyte growth factor, the LECT2 binding causes an an

291 p53-expressing cells were more sensitive to hepatocyte growth factor, the ligand for MET, leading to

292 loop that is initiated by cardiac-expressed hepatocyte growth factor to direct T cells into the hear

293 d MDCK cells grown as cysts and treated with hepatocyte growth factor to model tubulogenesis.

294 Binding of the hepatocyte growth factor to the cell surface receptor of

295 a combination of angiopoietin-1, angiogenin, hepatocyte growth factor, transforming growth factor-alp

296 ctivation of BAD, and that the resistance of hepatocyte growth factor-treated human melanoma cells to

297 ctin) and including relevant growth factors (hepatocyte growth factor, vascular endothelial growth fa

298 SVPs and CSCs secrete similar amounts of hepatocyte growth factor, vascular endothelial growth fa

299 bound to sSDC1 heparan sulfate chains (i.e. hepatocyte growth factor) was transported to the nucleus

300 ression of uPA regulated the level of active hepatocyte growth factor, which is required for muscle f